晚期肝细胞癌的免疫治疗现状综述
A Status Quo Review of Immunotherapy for Advanced Hepatocellular Carcinoma
DOI: 10.12677/ACM.2021.1112849, PDF,  被引量   
作者: 王靖超, 安斌斌, 王志鑫, 张灵强, 王海久, 樊海宁, 周 瀛*：青海大学附属医院肝胆胰外科，青海 西宁
关键词: 肝细胞癌；免疫治疗；PD-1；综述；Hepatocellular Carcinoma (HCC)； Immunotherapy； PD-1； Review
摘要: 肝癌是世界范围内最常见的恶性肿瘤之一，其中，肝细胞癌(Hepatocellular carcinoma, HCC)占据主要地位(约85%~90%)，目前，HCC在全球恶性肿瘤相关死因中占据前列。并且因为乙型肝炎病毒(Hepatitis B virus, HBV)在我国流行，我国肝细胞癌患者的发病平均年龄比欧美等发达国家年轻8岁，这也是造成社会负担巨大的重要原因之一。肝细胞癌的治疗方式一直在不断地求索和创新中，虽然新的治疗方式已经在临床普遍应用，但是对晚期肝细胞癌患者的治疗收获还远远不能满足我们和HCC患者的期望值。免疫检查点抑制剂(Immune checkpoint inhibitors, ICIs)可以通过阻断免疫检查点分子受体配体的结合等方式，使趋向衰竭的T细胞功能再次恢复，从根本上抑制癌细胞的免疫逃逸。本文就目前免疫抑制剂在HCC领域的探索作一综述。
Abstract: Liver cancer is one of the most common malignant tumors worldwide, among which hepatocellular carcinoma (HCC) occupies the main position (about 85%~90%), and currently, HCC occupies the forefront of malignant tumor-related causes of death worldwide. In addition, due to the prevalence of hepatitis B virus (HBV) in China, the average age of HCC patients in China is 8 years younger than that in developed countries such as Europe and the United States, which is one of the important reasons for the huge social burden. The therapeutic methods for HCC have been constantly seeking and innovating. Although new therapeutic methods have been widely applied in clinical practice, the therapeutic harvest for advanced HCC patients is far from meeting our and HCC patients’ expectations. Immune checkpoint inhibitors (ICIs) can restore the function of T cells that have a trend of exhaustion by blocking the binding of receptor ligand of immune checkpoint molecules, and fundamentally inhibit the immune escape of cancer cells. This article reviews the recent development of immunosuppressive agents in HCC.
文章引用：王靖超, 安斌斌, 王志鑫, 张灵强, 王海久, 樊海宁, 周瀛. 晚期肝细胞癌的免疫治疗现状综述[J]. 临床医学进展, 2021, 11(12): 5740-5746. https://doi.org/10.12677/ACM.2021.1112849

参考文献

[1] Rao, Q., et al. (2020) Clinical Benefits of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta Analysis. Hepatology International, 14, 765-775.
[2] 应倩, 汪源. 肝癌流行现况和趋势分析[J]. 中国肿瘤, 2020, 29(3): 185-191.
[3] Tella, S.H., Mahipal, A., Kommalapati, A. and Jin, Z. (2019) Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. OncoTargets and Therapy, 12, 10335-10342. [Google Scholar] [CrossRef] 
[4] Siegel, A.B., Olsen, S.K., Magun, A. and Brown, R.S. (2010) Sorafenib: Where Do We Go from Here? Hepatology, 52, 360-369. [Google Scholar] [CrossRef] [PubMed]
[5] Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine, 363, 711-723. [Google Scholar] [CrossRef] 
[6] Nishijima, T.F., Shachar, S.S., Nyrop, K.A. and Muss, H.B. (2017) Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Oncologist, 22, 470-479. [Google Scholar] [CrossRef] [PubMed]
[7] Carretero-Gonzalez, A., Lora, D., Ghanem, I., Zugazagoitia, J., Castellano, D., Sepulveda, J.M., Lopez-Martin, J.A., et al. (2018) Analysis of Response Rate with ANTI PD-1/PD-L1 Monoclonal Antibodies in Advanced Solid Tumors: A Meta-Analysis of Randomized Clinical Trials. Oncotarget, 9, 8706-8715. [Google Scholar] [CrossRef] [PubMed]
[8] Boussiotis, V.A. (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. The New England Journal of Medicine, 375, 1767-1778. [Google Scholar] [CrossRef] 
[9] Moskovitz, J., Moy, J. and Ferris, R.L. (2018) Immunotherapy for Head and Neck Squamous Cell Carcinoma. Current Oncology Reports, 20, 22. [Google Scholar] [CrossRef] [PubMed]
[10] Crispe, I.N. (2003) Hepatic T Cells and Liver Tolerance. Nature Reviews Immunology, 3, 51-62. [Google Scholar] [CrossRef] [PubMed]
[11] Karimi, M.H., Geramizadeh, B. and Malek-Hosseini, S.A. (2015) Tolerance Induction in Liver. International Journal of Organ Transplantation Medicine, 6, 45-54.
[12] Tiegs, G. and Lohse, A.W. (2010) Immune Tolerance: What Is Unique about the Liver. Journal of Autoimmunity, 34, 1-6. [Google Scholar] [CrossRef] [PubMed]
[13] Carambia, A., Freund, B., Schwinge, D., Heine, M., Laschtowitz, A., Huber, S., et al. (2014) TGF-β-Dependent Induction of CD4+ CD25+ Foxp3+ Tregs by Liver Sinusoidal Endothelial Cells. Journal of Hepatology, 61, 594-599. [Google Scholar] [CrossRef] [PubMed]
[14] Makarova-Rusher, O.V., Medina-Echeverz, J., Duffy, A.G. and Greten, T.F. (2015) The Yin and Yang of Evasion and Immune Activation in HCC. Journal of Hepatology, 62, 1420-1429. [Google Scholar] [CrossRef] [PubMed]
[15] Okusaka, T. and Ikeda, M. (2018) Immunotherapy for Hepatocellular Carcinoma:Current Status and Future Perspectives. ESMO Open, 3, e000455. [Google Scholar] [CrossRef] [PubMed]
[16] Vandeven, N. and Nghiem, P. (2014) Pathogen-Driven Cancers and Emerging Immune Therapeutic Strategies. Cancer Immunology Research, 2, 9-14. [Google Scholar] [CrossRef] 
[17] Lim, C.J., Lee, Y.H., Pan, L., Lai, L., Chua, C., Wasser, M., et al. (2018) Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut, 68, 916-927. [Google Scholar] [CrossRef] [PubMed]
[18] Lv, Y., Cui, M., Lv, Z., Lu, J., Zhang, X., Zhao, Z., et al. (2018) Expression and Significance of Peripheral Myeloid-Derived Suppressor Cells in Chronic Hepatitis B Patients. Clinics and Research in Hepatology and Gastroenterology, 42, 462-469. [Google Scholar] [CrossRef] [PubMed]
[19] Kondo, Y. and Shimosegawa, T. (2015) Significant Roles of Regulatory T Cells and Myeloid Derived Suppressor Cells in Hepatitis B Virus Persistent Infection and Hepatitis B Virus-Related HCCs. International Journal of Molecular Sciences, 16, 3307-3322. [Google Scholar] [CrossRef] [PubMed]
[20] El-Khoueiry, A.B., Melero, I., Crocenzi, T.S., Welling, T.H., Yau, T.C., Yeo, W.N., Chopra, A., et al. (2015) Phase I/II Safety and Antitumor Activity of Nivolumab in Patients with Advanced Hepatocellular Carcinoma (HCC): CA209-040. Journal of Clinical Oncology, 33, LBA101. [Google Scholar] [CrossRef] 
[21] El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., Kim, T.Y., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. [Google Scholar] [CrossRef] 
[22] Kudo, M., Finn, R.S., Qin, S., Han, K.H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.W., Han, G., Jassem, J., Blanc, J.F., Vogel, A., Komov, D., Evans, T.R.J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M. and Cheng, A.L. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173. [Google Scholar] [CrossRef] 
[23] Finn, R.S., Ikeda, M., Zhu, A.X., Sung, M.W., Baron, A.D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., Pracht, M., Mamontov, K., Meyer, T., Kubota, T., Dutcus, C., Saito, K., Siegel, A.B., Dubrovsky, L., Mody, K. and Llovet, J.M. (2020) Phase Ib Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 38, 2960-2970. [Google Scholar] [CrossRef] 
[24] Finn, R.S., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T.Y., Kudo, M., Breder, V., Merle, P., Kaseb, A.O., Li, D., Verret, W., Xu, D.Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Wang, Y., Lim, H.Y., Zhu, A.X. and Cheng, A.L. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. [Google Scholar] [CrossRef] 
[25] Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., Shao, G., Zhang, Y., Xu, L., Yin, T., Liu, J., Ren, Z., Xiong, J., Mao, X., Zhang, L., Yang, J., Li, L., Chen, X., Wang, Z., Gu, K., Chen, X., Pan, Z., Ma, K., Zhou, X., Yu, Z., Li, E., Yin, G., Zhang, X., Wang, S. and Wang, Q. (2021) Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-Label, Phase II Trial. Clinical Cancer Research, 27, 1003-1011. [Google Scholar] [CrossRef] 
[26] Zhang, T.-Q., et al. (2021) 946P Hepatic Artery Infusion Chemotherapy (HAIC) Combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma (HCC) in BCLC Stage C: A Prospective, Single-Arm, Phase II Trial (TRIPLET Study). Annals of Oncology, 32, S825. [Google Scholar] [CrossRef] 

为你推荐